Regulatory Pathways and Classification

AI tools used in radiology may be regulated as medical devices depending on their intended use and on jurisdictional rules. Regulatory pathways vary and may require premarket submissions that include evidence of safety and effectiveness clinical validation and risk mitigation strategies. Classification depends on the level of risk posed by the tool and on whether it provides diagnostic outputs or workflow assistance. Early engagement with regulatory experts and with institutional risk committees helps clarify classification and data requirements and informs study design for validation and for post market surveillance.

Documentation Validation and Post Market Surveillance

Regulatory submissions typically require detailed documentation of data provenance model training methods validation results and performance metrics with uncertainty estimates. Clinical validation plans should include representative populations and device types and predefined success criteria. Post market surveillance monitors real world performance and captures adverse events and model drift and institutions must have processes to report significant safety issues to regulators. Version control and change management ensure that model updates are evaluated and documented and that regulatory obligations are met for modified devices.

Institutional Policies and Ethical Oversight

Beyond external regulation institutions implement local policies that govern procurement validation deployment and monitoring of AI tools. Multidisciplinary governance committees review vendor claims validation evidence and risk assessments and approve clinical use cases and escalation pathways. Ethical oversight addresses issues such as bias transparency and patient consent for AI assisted care and ensures that tools are used in ways that align with institutional values. Training for clinicians and technologists on the limits and appropriate use of AI supports safe integration into clinical practice and protects patient welfare.